Another single-center study prospectively enrolled 58 patients affected by KRAS positive advanced NSCLC and treated with single-agent immunotherapy or chemotherapy for whom frozen plasma samples were available at two time points (baseline vs 3 or 4 weeks) [13]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.